First Tracks Biotherapeutics, Inc. Ordinary Shares TRAX
i
Market datapartial · fetched 2026-11-13T02:12:06.580Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T21:00:06.329900258Z
FundamentalsAlpha Vantage · unavailable
First Tracks Biotherapeutics, Inc. Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 40.82 | 164.5% | 19.1% | |||
| 25Δ | 58.29 | 152.3% | 22.6% | 43.04 | 141.2% | 14.9% |
| 30Δ | 54.93 | 131.3% | 16.1% | 45.12 | 119.9% | 11.0% |
| 35Δ | 53.44 | 123.5% | 13.6% | 46.07 | 113.2% | 9.6% |
| 40Δ | 51.96 | 115.6% | 11.1% | 47.03 | 106.5% | 8.2% |
| 45Δ | 50.47 | 107.7% | 8.6% | 47.99 | 99.8% | 6.8% |
| 50Δ | 49.35 | 104.6% | 7.1% | 48.95 | 93.1% | 5.4% |
| 55Δ | 48.41 | 103.6% | 6.2% | 49.91 | 86.4% | 4.0% |
| 60Δ | 47.46 | 102.6% | 5.2% | 50.88 | 85.7% | 3.4% |
| 65Δ | 46.52 | 101.6% | 4.2% | 51.85 | 85.7% | 2.8% |
| 70Δ | 45.57 | 100.6% | 3.3% | 52.81 | 85.7% | 2.3% |
| 75Δ | 44.36 | 102.5% | 2.5% | 53.78 | 85.7% | 1.8% |
| 80Δ | 42.76 | 108.7% | 2.0% | 54.75 | 85.7% | 1.3% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 40.82
- IV
- 164.5%
- B/E move
- 19.1%
25Δ
- Pseudo strike
- 58.29
- IV
- 152.3%
- B/E move
- 22.6%
- Pseudo strike
- 43.04
- IV
- 141.2%
- B/E move
- 14.9%
30Δ
- Pseudo strike
- 54.93
- IV
- 131.3%
- B/E move
- 16.1%
- Pseudo strike
- 45.12
- IV
- 119.9%
- B/E move
- 11.0%
35Δ
- Pseudo strike
- 53.44
- IV
- 123.5%
- B/E move
- 13.6%
- Pseudo strike
- 46.07
- IV
- 113.2%
- B/E move
- 9.6%
40Δ
- Pseudo strike
- 51.96
- IV
- 115.6%
- B/E move
- 11.1%
- Pseudo strike
- 47.03
- IV
- 106.5%
- B/E move
- 8.2%
45Δ
- Pseudo strike
- 50.47
- IV
- 107.7%
- B/E move
- 8.6%
- Pseudo strike
- 47.99
- IV
- 99.8%
- B/E move
- 6.8%
50Δ
- Pseudo strike
- 49.35
- IV
- 104.6%
- B/E move
- 7.1%
- Pseudo strike
- 48.95
- IV
- 93.1%
- B/E move
- 5.4%
55Δ
- Pseudo strike
- 48.41
- IV
- 103.6%
- B/E move
- 6.2%
- Pseudo strike
- 49.91
- IV
- 86.4%
- B/E move
- 4.0%
60Δ
- Pseudo strike
- 47.46
- IV
- 102.6%
- B/E move
- 5.2%
- Pseudo strike
- 50.88
- IV
- 85.7%
- B/E move
- 3.4%
65Δ
- Pseudo strike
- 46.52
- IV
- 101.6%
- B/E move
- 4.2%
- Pseudo strike
- 51.85
- IV
- 85.7%
- B/E move
- 2.8%
70Δ
- Pseudo strike
- 45.57
- IV
- 100.6%
- B/E move
- 3.3%
- Pseudo strike
- 52.81
- IV
- 85.7%
- B/E move
- 2.3%
75Δ
- Pseudo strike
- 44.36
- IV
- 102.5%
- B/E move
- 2.5%
- Pseudo strike
- 53.78
- IV
- 85.7%
- B/E move
- 1.8%
80Δ
- Pseudo strike
- 42.76
- IV
- 108.7%
- B/E move
- 2.0%
- Pseudo strike
- 54.75
- IV
- 85.7%
- B/E move
- 1.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 85.80% | |
| 81.18% | |
| 81.01% | |
| 78.16% | |
| 81.43% | |
| 82.37% | |
| 83.08% | |
| 80.01% | |
| 82.20% | |
| 81.39% |
Biotechnology
TRDA
Entrada Therapeutics Inc. (TRDA) is a forward-thinking biotechnology company focused on creating innovative therapies for severe diseases characterized by significant unmet…
More →TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious neurology-mediated…
More →TSHA
Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic…
More →TTRX
Turn Therapeutics Inc., is a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company is headquartered in Westlake Village,…
More →TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The…
More →TWST
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company is headquartered in South San Francisco, California.
More →